Healthcare provider profile · identity verified

Stephen Matthew Asma, MD

Family Practice · DE PERE, WI · NPI 1639103187

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lisinopril	Lisinopril	348	92
Simvastatin	Simvastatin	330	87
Levothyroxine Sodium	Levothyroxine Sodium	299	77
Atorvastatin Calcium	Atorvastatin Calcium	285	80
Metoprolol Succinate	Metoprolol Succinate	211	60
Losartan Potassium	Losartan Potassium	207	60
Amlodipine Besylate	Amlodipine Besylate	205	55
Metformin Hcl	Metformin Hcl	191	50
Hydrochlorothiazide	Hydrochlorothiazide	164	51
Tamsulosin Hcl	Tamsulosin Hcl	161	47
Alprazolam	Alprazolam	143	32
Glipizide	Glipizide	142	37
Omeprazole	Omeprazole	142	39
Pantoprazole Sodium	Pantoprazole Sodium	134	34
Tramadol Hcl	Tramadol Hcl	115	27
Warfarin Sodium	Warfarin Sodium	106	13
Allopurinol	Allopurinol	105	33
Sertraline Hcl	Sertraline Hcl	101	27
Meloxicam	Meloxicam	100	44
Gabapentin	Gabapentin	99	30
Albuterol Sulfate Hfa	Albuterol Sulfate	97	32
Zolpidem Tartrate	Zolpidem Tartrate	95	21
Potassium Chloride	Potassium Chloride	88	27
Furosemide	Furosemide	86	26
Metoprolol Tartrate	Metoprolol Tartrate	82	24
Donepezil Hcl	Donepezil Hcl	69	17
Eliquis	Apixaban	61	16
Citalopram Hbr	Citalopram Hydrobromide	57	15
Diclofenac Sodium	Diclofenac Sodium	53	16
Fluticasone Propionate	Fluticasone Propionate	53	23
Clonidine Hcl	Clonidine Hcl	52	14
Lorazepam	Lorazepam	50	18
Pravastatin Sodium	Pravastatin Sodium	50	14
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	49	suppressed
Januvia	Sitagliptin Phosphate	47	suppressed
Clopidogrel	Clopidogrel Bisulfate	44	14
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	44	29
Atenolol	Atenolol	42	suppressed
Lovastatin	Lovastatin	42	11
Oxybutynin Chloride	Oxybutynin Chloride	42	11
Prednisone	Prednisone	42	22
Synthroid	Levothyroxine Sodium	42	suppressed
Trazodone Hcl	Trazodone Hcl	37	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	36	suppressed
Ezetimibe	Ezetimibe	35	suppressed
Clonazepam	Clonazepam	34	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	34	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	34	suppressed
Bupropion Hcl Sr	Bupropion Hcl	33	suppressed
Jardiance	Empagliflozin	33	suppressed
Buspirone Hcl	Buspirone Hcl	32	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	32	11
Azithromycin	Azithromycin	31	27
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	29	16
Doxycycline Hyclate	Doxycycline Hyclate	29	18
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	29	suppressed
Duloxetine Hcl	Duloxetine Hcl	28	suppressed
Propranolol Hcl Er	Propranolol Hcl	28	suppressed
Cephalexin	Cephalexin	27	11
Quetiapine Fumarate	Quetiapine Fumarate	27	suppressed
Estradiol	Estradiol	26	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	26	suppressed
Amoxicillin	Amoxicillin	25	suppressed
Carvedilol	Carvedilol	25	suppressed
Enalapril Maleate	Enalapril Maleate	24	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Pregabalin	Pregabalin	24	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Verapamil Er	Verapamil Hcl	24	suppressed
Xarelto	Rivaroxaban	24	suppressed
Famotidine	Famotidine	23	suppressed
Metformin Hcl Er	Metformin Hcl	23	suppressed
Temazepam	Temazepam	23	suppressed
Calcitonin-Salmon	Calcitonin,salmon,synthetic	22	suppressed
Flecainide Acetate	Flecainide Acetate	20	suppressed
Memantine Hcl	Memantine Hcl	20	suppressed
Terazosin Hcl	Terazosin Hcl	20	suppressed
Bumetanide	Bumetanide	19	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	19	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	19	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Tizanidine Hcl	Tizanidine Hcl	18	suppressed
Diazepam	Diazepam	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Valsartan	Valsartan	17	suppressed
Finasteride	Finasteride	16	suppressed
Colestipol Hcl	Colestipol Hcl	15	suppressed
Montelukast Sodium	Montelukast Sodium	15	suppressed
Naproxen	Naproxen	15	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	14
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	14	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	13	suppressed
Celecoxib	Celecoxib	13	suppressed
Icosapent Ethyl	Icosapent Ethyl	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	11
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Eletriptan Hbr	Eletriptan Hydrobromide	12	suppressed
Hydrocortisone	Hydrocortisone	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	suppressed
Propafenone Hcl	Propafenone Hcl	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	suppressed
Divalproex Sodium Er	Divalproex Sodium	11	suppressed
Gemfibrozil	Gemfibrozil	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed
Spironolactone	Spironolactone	11	suppressed
Tegretol	Carbamazepine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error